Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes the pharmacology, mechanisms, and clinical efficacy of topical immunotherapy for alopecia areata but reports no new clinical results.

In this randomized, double-blind, placebo-controlled trial, researchers found that a multi-targeted cosmetic formulation containing TrinogeniX™ significantly increased hair density and thickness in individuals with androgenetic alopecia without adverse effects, suggesting it as a potential safe and effective treatment option.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This study found that proteins secreted by early-passage dermal papilla cells, including SDF1, MMP3, biglycan, and LTBP1, may play significant roles in hair follicle regeneration.

This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.

This study found that combining herbal extracts with PRP increased human dermal papilla cell proliferation via ERK and Akt protein regulation, suggesting its potential for developing hair growth therapies.

This study explored the effects of DPP, a 15-PGDH inhibitor, on human follicle dermal papilla cells damaged by dihydrotestosterone and observed that DPP enhanced wound healing, reduced reactive oxygen species, and increased hair growth in ex vivo human hair follicle cultures.

In this study, a treatment combining fractional 1927nm laser with a growth factor serum was found to increase hair density and diameter in patients with androgenic alopecia over six months, without side effects, and three treatments at 4-weekly intervals were deemed most effective.

In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This review discusses the transformative potential of direct-to-consumer (DTC) hair regrowth solutions and reports no clinical results; it emphasizes innovation, personalization, and trust in reshaping the industry.

This case report suggests that topical tacrolimus may effectively manage erosive pustular dermatosis of the scalp and reverse skin atrophy, although long-term use requires monitoring for side effects.

This study suggests that pulsed wave photobiomodulation could be a promising treatment for androgenetic alopecia by enhancing dermal papilla cell function through specific light parameters, particularly frequency.

This study found that 5-bromo-3,4-dihydroxybenzaldehyde (BDB) promoted hair growth in rat vibrissa follicles by activating Wnt/β-catenin and autophagy pathways and inhibiting the TGF-β pathway in dermal papilla cells.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

In this study, VD(3) pretreatment increased hair follicle formation in a rat model by promoting dermal papilla cell differentiation, suggesting potential for hair regeneration therapy.

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

This study found that injecting PDGF-AA and -BB into mouse skin immediately triggered the hair growth cycle's anagen phase, suggesting potential treatment options for certain types of alopecia.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

This study reported that therapeutic make-up significantly improves the long-term quality of life for patients with facial dermatoses, showing a sustained benefit one year after application, particularly in younger patients.

In this study, researchers found that topical application of the diabetes medication Sitagliptin in mice accelerates hair follicle regeneration and reduces fibrosis, suggesting it could be repurposed to treat hair loss conditions like alopecia.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This study reported that platelet-rich plasma therapy combined with intralesional triamcinolone acetonide was beneficial for patients with alopecia totalis, helping them reduce reliance on oral immunosuppressants.

Prostaglandin helps regenerate hair follicles after radiation damage.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

This laboratory study found that activated platelet‐rich plasma supernatant enhanced hair growth signaling pathways in cultured human dermal papilla cells, suggesting potential for treating androgenic alopecia.

This study observed significant improvements in hair loss and hair density among adults using USPlus DERM Topical serum daily for 12 weeks, with 90.9% of participants noticing better hair loss/density and rating satisfaction at an average of 7.7 out of 10.